Psychiatrists presented studies at the 151st annual meeting of the American Psychiatric Association in Toronto on June 8 on the first member of a new class of drugs, the selective noradrenaline (or norepinephrine) reuptake inhibitors, which they state appears to be efficacious in the treatment of severe depression.
Reboxetine has been on the market in the United Kingdom for close to one year. Reboxetine's side effect profile was comparable to Prozac. The primary adverse effects associated with use of the norepinephrine reuptake inhibitor were headache, constipation, hypotension and diaphoresis.
This is the first that I have seen of this new class of drugs for depression. They will probably be introduced in this country in the near future once the FDA provides their approval. If you look at issue #41, you will find a description of the use of tryptophan for depression. It works well were Prozac would work as they both serve to increase serotonin levels. However, to increase norepinephrine levels, other amino acids, like tyrosine, can be used.